MEDI-551 as Maintenance Therapy After Allogeneic Stem Cell Transplant in Multiple Myeloma
Status:
Terminated
Trial end date:
2018-04-15
Target enrollment:
Participant gender:
Summary
Determine the progression free survival of high-risk or relapsed Multiple Myeloma (MM)
patients undergoing non-myeloablative bone marrow allogeneic transplantation (NM-AlloSCT)
followed by maintenance therapy with MEDI-551.
Phase:
Phase 2
Details
Lead Sponsor:
Sidney Kimmel Comprehensive Cancer Center Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins